Navigator Medicines, Inc.
StreetZero Signal 77
About Navigator Medicines, Inc.
Navigator Medicines is a clinical-stage biotechnology company focused on advancing bispecific antibodies for targeted immune regulation and restoration in autoimmune diseases. Founded in 2024 as a subsidiary of Sera Medicines, LLC, the company specializes in OX40L inhibition and develops bispecific antibodies that block both OX40L and TNFฮฑ. It acquired the NAV-240 asset and related OX40L-targeted portfolio from IMBiologics Corp. The company is headquartered in Scotch Plains, NJ.
LATEST FUNDINGSeries A
$10.0M
Announced 2026-09-25
TOTAL RAISED$100M
IN THE NEWS
- ๐ Forbion Co-leads $100 Million Series A Funding | Forbion
- ๐ Navigator Medicines Secures $100M Series A for NAV-240, a Promising Bispecific Antibody for Autoimmune Diseases
- ๐ Navigator Medicines | Forbion
- ๐ Navigator Medicines 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- ๐ Navigator Medicines - Products, Competitors, Financials, Employees, Headquarters Locations
EMPLOYEESโ
FOUNDED2024
HQScotch Plains, NJ, USA
Industry
Biotechnology
Tags
BiotechnologyBispecific AntibodiesAutoimmune DiseasesSeries A
Key highlights
- Closed $100M Series A in August 2024 co-led by Forbion and RA Capital Management.
- Acquired NAV-240 and OX40L-targeted portfolio from IMBiologics Corp.
- Develops bispecific antibodies simultaneously blocking OX40L and TNFฮฑ pathways.
- Founded in 2024 as a subsidiary of Sera Medicines, LLC.
- Clinical-stage company focused on autoimmune and inflammatory disorders.
Ask StreetZero about Navigator Medicines, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account